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INTRODUCTION
Protein kinase C epsilon (PKCε) is known to increase endothelial nitric oxide synthase (eNOS)
activity by binding to a specific receptor for activated C kinase (RACK-1), facilitating its
translocation from the cytosol to the cell membrane for phosphorylation of eNOS at serine-1177
to augment activity [1,2]. Previous in vitro and in vivo animal studies have demonstrated that
PKCε activation stimulates eNOS activity, increasing nitric oxide (NO) release; whereas a peptide
inhibitor that disrupts PKCε interaction with RACK-1 results in decreased NO release [3,4,5,6,7].
However, the modulation of PKC-mediated eNOS activity (Figure 1) is not well known in human
endothelial cells. Moreover, elucidating the role of PKCε in regulating eNOS activity would be
essential in the clinical setting of ischemic heart disease. Re-establishing blood flow after
thrombus removal results in endothelial dysfunction that is characterized by limited NO
bioavailability and excess generation of reactive oxygen species (ROS) by eNOS during reperfusion
(Figure 2).

HYPOTHESIS
We hypothesize that Myr-PKCε+ would increase NO release, whereas Myr-PKCε- would
decrease NO release from cultured HUVECs in the absence and presence of Ach.

METHODS
Measurement of NO release from cultured HUVECs: Single-donor HUVECs (Lonza,
Walkersville, MD) at passages 3-4 were grown to confluence in 6-well (106 cells/well) plates. NO
release was measured in real time using a calibrated NO electrode following the administration of
10 μM Myr-PKCε+ or 10 μM Myr-PKCε- treatments in the absence or presence of 10 μM Ach
stimulation of NO release. All treatments were prepared in endothelial growth media (EGM). Basal
NO release was determined by measuring the difference between wells with and without cells.

RESULTS
Basal NO release (83±12 pmol) was determined by measuring the difference between wells
with and without HUVECs (n=9, P<0.05). In the absence of Ach stimulation, Myr-PKCε+
treatments significantly enhanced NO release to 136±13 pmol (n=6, p<0.05) and Myr-PKCεattenuated total NO release to 16±27 pmol (n=7, p<0.05) compared to basal levels.
As a positive control, 10 μM Ach significantly enhanced NO release to 153±11 pmol above
basal levels (p<0.05, n=20). In the presence of Ach simulation, Myr-PKCε+ still significantly
increased NO release above basal levels to 129±17 pmol (p<0.05, n=8) and Myr-PKCεdecreased NO release to 34±12 pmol, (p<0.05, n=7) compared to basal levels, as shown in
Figure 5.

Statistical Analysis: All data in the figures are presented as means ± S.E.M. ANOVA analysis using
Therefore, we aim to demonstrate enhancement and attenuation of NO release in cultured
HUVECs using cell-permeable, myristic-acid conjugated PKCε activator (Myr-PKCε+), MyrHDAPIGYD (MW = 1097 g/mol), and inhibitor (Myr-PKCε-), N-Myr-EAVSLKPT (MW = 1054 g/mol),
in the absence and presence of acetylcholine (Ach). Ach is a well-established positive control to
activate eNOS via calcium calmodulin (CAM) and promote NO release from vascular endothelial
cells [7, 8]. Determining NO release using selective cell permeable PKCε activator (Myr-PKCε+)
and inhibitor peptides (Myr-PKCε-) in cultured HUVECs under normoxic conditions would provide
a foundation to test these peptides under hypoxic-reoxygenation conditions when eNOS would
be uncoupled and produce ROS instead of NO release.

Student-Neuman-Keuls was used to assess statistical difference in NO release between basal
levels vs Myr-PKCε+ treated or Myr-PKCε- treated cultured HUVECs in the absence and presence
of Ach stimulation (Ach or EGM); p<0.05 were considered statistically significant.

Figure 3. Illustration of NO electrode calibration setup (left), calibration curve (top right) and
HUVEC NO measurement in 6-well plates (bottom). The NO electrode was calibrated based on
the following reaction: 2KNO2 + 2KI + 2H2SO4 → 2NO + I + 2H2O +2K2SO4 (e.g. y = 0.9346x +
3.4828; R² = 0.997) that corresponded to a 25 nM to 200 nM range (right). Dose responses are
indicated by red arrows.
Figure 1. Mechanism of action of Myr-PKCε activator (Myr-HDAPIGYD) and Myr-PKCε
inhibitor (N-Myr-EAVSLKPT), adapted from [1]. When activated by diacylglycerol (DG), PKCε
binds to specific receptor for activated C kinase (RACK) domain which translocates PKCε to
interact with substrates (e.g. eNOS) to produce a physiologic response (left panel). Myr-PKCε+
(in green) prolongs the active confirmation of PKCε to facilitate increased interaction with
RACK, resulting in increased physiological response. Myr-PKCε- (in red) inhibits PKCε or
translocation by binding to its specific RACK to reduce physiologic response (right panel).

CONCLUSION
These results suggest that in cultured HUVECs, Myr-PKCε+ presumably increases
NO release via activation of eNOS, whereas Myr-PKCε- attenuates eNOS activity by
inhibiting its phosphorylation; thus these peptides demonstrate comparable
effects across species in regulating NO release. The understanding of the role of
eNOS modulation is important for developing therapeutic interventions in the
context of human organ-ischemia reperfusion injury, in which uncoupled eNOS
produces ROS instead of NO.

Enhanced NO release in cultured HUVECs after the administration of PKC activator (PKCε+)

Attenuated NO release in cultured HUVECs after the administration of PKC inhibitor (PKCε-)

Figure 2. Schematic representation of PKC regulation of eNOS and mitochondrial-derived
superoxide (O2-) release in myocardial I/R, adapted from [5]. I/R insult activates PKC and
opening of mitochondrial potassium ATP channels resulting in uncoupled eNOS activity by
PKCε.

Figure 5. NO release (picomoles) in cultured HUVECs (106 cells/well) following Myr-PKCε+
(10 μM) and Myr-PKCε- (10 μM) treatments in the absence and presence of ACh
stimulation. EGM represents negative control containing only endothelial growth media
without Ach; *p<0.05 vs. Basal values; #p<0.05 vs. Myr-PKCε+ treatments.

Figure 4. Illustration of real-time NO release measurements in cultured HUVECs using calibrated
NO electrode (left). Representative tracings of NO released from cultured HUVECs was measured
after administration of the 10 μM PKCε activator (top right) or 10 μM inhibitor (bottom right) in
the absence and presence of Ach (10 μM). Basal NO release was determined by measuring the
difference between a well containing cells and one well containing only endothelial growth media
(EGM) without cells. Picoamp responses (red arrows) were converted to picomoles/106 cells
based on the calibration curve of the NO electrode.
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